Introduction {#S1}
============

Guanylin and uroguanylin are endogenous hormones involved in intestinal fluid homeostasis and bowel function of the gastrointestinal tract in several species; these hormones activate the guanylate cyclase-C (GC-C), a type I transmembrane receptor essentially expressed on the apical surface of intestinal epithelial cells. Receptor activation by selective GC-C agonists, such as guanylin and uroguanylin, responds to several signals by catalyzing the conversion of guanosine triphosphate to cyclic guanosine-3′,5′ monophosphate (GMPc) ([@B37]). The increase of intracellular concentrations of the GMPc second messenger triggers a signaling cascade that causes an uncontrolled release of electrolytes and water into the intestinal lumen, resulting in secretory diarrhea ([@B12]). The intracellular GMPc accumulation proceeds to the PKGII-dependent (protein kinase II) phosphorylation of the cystic fibrosis transmembrane regulator (CFTR), stimulating transepithelial secretion of chloride and bicarbonate ions, and inhibition of sodium absorption by the sodium/hydrogen exchanger 3 (NHE3): these effects results in a net efflux of ions and water into the lumen ([@B21]; [@B49]; [@B24]; [@B1]).

Guanylate cyclase-C is also involved in mucosal barrier function, inflammation, modulation of intestinal cell proliferation, and pain sensation ([@B56]; [@B21]; [@B22]; [@B8]).

Guanylate cyclase-C is encoded by the *GUCY2C* gene, and represents one of seven mammalian transmembrane guanylate cyclase receptors ([@B21]; [@B20]). Its transcript is mainly expressed on epithelial cells of the gastrointestinal tract and was at first identified as the receptor for the bacterial heat-stable enterotoxin (STa), produced by several enteric pathogens and responsible for the traveler's diarrhea ([@B36]; [@B51]).

Endogenous ligands of GC-C, guanylin and uroguanylin, are encoded by *GUCA2A* and *GUCA2B* genes. *GUCA2A, GUCA2B* and *GUCY2C* are down-regulated in human chronic inflammatory intestinal diseases with dysfunctional epithelial electrolyte regulation ([@B11]). This increased knowledge on the activities triggered by GC-C activation has guided the development of novel therapeutic approaches to gastrointestinal disorders ([@B55]), including constipation, which resulted in the clinical use of linaclotide, a synthetic 14-peptide, potent and selective agonist of GC-C and, more recently, of plecanatide and dolcanatide ([@B24]; [@B46]; [@B3]; [@B32]).

Although several prokinetic drugs are administered to horses with gastrointestinal hypomotility in veterinary practice, their use and efficacy are not well established yet ([@B53]); among these, bethanecol and neostigmine are cholinomimetic drugs that can be administered to horses, with cholinergic side effects preventing their routine use ([@B43]) whereas the efficacy of metoclopramide and domperidone needs to be further investigated, irrespective of being proposed in the treatment of hypomotility, ([@B40]). Other drugs with established prokinetic effect in horses include erythromycin, naloxone, and lidocaine in horses affected by post-operative ileus ([@B43]). Cisapride can be used in managing persistent large colon impaction in horses, equine grass sickness, and as a preventative for postoperative ileus. However, due to serious cardiac side effects in humans this drug has been withdrawn from the market ([@B41]). A specific treatment for hypomotility in horse has therefore not yet been established, therefore the identification of drugs able to enhance the intestinal transit, relieve pain and soften the feces could be an extremely valuable tool in equine internal medicine.

In this context, in this paper, the expression of guanylin, uroguanylin and GC-C receptors, in different gastrointestinal tracts of horse has been investigated for the first time, with the aim of developing new therapeutic strategies for the treatment of gastrointestinal diseases in horses.

Materials and Methods {#S2}
=====================

Animals and Samples Collection {#S2.SS1}
------------------------------

Tissue samples were collected from six female, mixed breed horses (5--9 years old, mean age: 7.2 ± 1.5 SD). All animals had no history of gastrointestinal disorders and were slaughtered at a public abattoir. The Animal Care Committee of University of Camerino approved the study with authorization number E81AC.8/D.

Full-thickness samples were collected immediately *post mortem* from the stomach, duodenum, jejunum, ileum, head and body of cecum, left and right dorsal colon, left and right ventral colon, pelvic flexure, transverse colon, descending colon and rectum. All samples were immediately frozen in liquid nitrogen and then stored at --80°C.

RNA Extraction {#S2.SS2}
--------------

Total RNA of all samples was extracted from 100 mg of ground tissue using the Trizol Plus RNA purification kit (Ambion, Life Technologies, Monza, Italy) according to the manufacturer's instructions, and checked for integrity and purity of nucleic acid as previously described ([@B9]; [@B48]).

qRT-PCR Assays {#S2.SS3}
--------------

Total RNA (1 μg) of each sample was retrotranscripted using SuperScript^®^ IV Vilo Master Mix (Thermo Fisher Scientific, Rodano, Italy) according to the manufacturer's specifications. In addition, 50 ng/μl of each sample were used to prepare a bulk solution for each gastrointestinal tract. Preliminary qRT-PCR was run on these bulk solutions to optimize experimental conditions and sub-select the most relevant gastrointestinal tracts, prior to the qRT-PCR assay on single samples.

Primers for the genes of interest (*GUCA2a*, *GUCA2b* and *GUCY2c*) were designed based on available sequences using the Primer-BLAST suite ([Table 1](#T1){ref-type="table"}); primers for reference genes (*SDHA* and *HPRT*) were those identified by [@B19] and previously tested ([@B18], [@B17]; [@B14], [@B15]). Primers for the gene of interest were designed taking into account all previously established requirements ([@B14], [@B16]; [@B9]). For each pair, a preliminary qRT-PCR assay was performed on the tissue bulks to check for amplification of either non-specific products or primer-dimer artifacts, and the efficiency were calculated. The qRT-PCR reaction was carried out aliquoting 5 μl of a five-fold diluted cDNA and SYBR Select Master Mix for CFX (Thermo Fisher Scientific). The amplifications were performed in a CFX96 Touch instrument (Bio-Rad, Hercules, CA), each sample was run in triplicate with appropriate negative controls, under the same condition used in previous studies: 98°C for 3 min, then 45 cycles of 98°C for 10 s and 60°C for 15 s. Fluorescence data were collected at the end of the second step and, following cycling, the melting curve was determined in the range of 58--95°C with an increment of 0.01°C/s ([@B9]).

###### 

Primer combinations for the studied genes.

  **Gene**   **Accession Number**   **Forward**      **Reverse**     **Amplicon size**   **Intron size**
  ---------- ---------------------- ---------------- --------------- ------------------- -----------------
  *GUCA*     XM_0015031             CATGAACACCTTCC   AGGTCCTTGAGCT   126                 1048
  *2A*       67.2                   TGCTCTCT         TCTTCACT                            
  *GUCA*     XM_0014975             GCTGTGGTCTTCCT   CCAGGTCACTCAG   103                 1137
  *2B*       86.2                   AGTGCT           CTTCTTCA                            
  *GUCY*     XM_00150169            TCTTTTGACCTATG   TGCGAGAGTGAAG   142                 5356
  *2C*       8.3                    ACACCCACA        ACTGCAA                             

Sizes are expressed in base pairs.

Data Analyses {#S2.SS4}
-------------

Bio-Rad CFX Manager software (ver. 3.2.2) was utilized to analyze data, including reference genes stability through geNorm algorithm, available in the CFX Manager software (vers. 3.2.2) ([@B54]). The expression ratio of the genes of interest was normalized relative to the abundance of the two reference genes using the ΔΔCq method. Samples for each gene of interest were grouped as biological replicates (one bulk or 6 horses) and tissues (14 tissues or 6 tissues), and analyzed accordingly. Expression levels are presented as mean values with standard error in a base 2 logarithmic scale or in relative expression, the least expressed condition being selected as baseline. We exported qRT-fPCR data for the 6 horses group after normalization with reference genes, and performed analysis of variance (ANOVA) using Tukey--Kramer *post hoc* test for the comparison of mean values.

Western Blotting Analyses {#S2.SS5}
-------------------------

Tissues were homogenized in 50 mM Tris buffer, 150 mM KCl, 2 mM EDTA, pH 7.5 (1:5 weight/volume) and centrifuged at 13.000 × *g* for 20 min (4°C). Protein content was determined by the Bradford method ([@B10]) using bovine serum albumin (BSA) as standard. Tissues homogenates were analyzed through western blotting assays with the aim to measure guanylyl cyclase protein expression levels. In detail, for each sample 20 μg total proteins were loaded on 10% SDS-PAGE and electroblotted onto PVDF membranes. Successively, upon incubation with the specific antibody Anti-*GUCY2C* (ab213430, Abcam, Italy, [Supplementary Figure S2](#FS2){ref-type="supplementary-material"}) the immunoblot detections were carried out through Enhanced Chemiluminescence (ECL) western blotting analysis system (Amersham Pharmacia-Biotech). β-actin was used to check equal protein loading, stripping the membranes and incubating with the anti-β-actin primary antibody (Santa Cruz Biotechnology, Italy). The bands were quantified by using a previously described densitometric algorithm ([@B44]). Statistical analysis was executed using one-way ANOVA, followed by the Bonferroni *post hoc* test using Sigma-stat 3.1 software (SPSS, Chicago, IL, United States). *P* values \< 0.05 were considered to be significant.

Protein Sequence Alignment {#S2.SS6}
--------------------------

Guanylate cyclase-C amino acid sequences from different species were obtained from UniProt ([@B50]), and alignments and percent identity matrix analysis were performed using Clustal Omega ([@B47]) ver. 2.1, with all settings kept to default.

UniProt accession numbers of protein sequences used are: *Equus caballus*: A0A3Q2L9C5; *Monodelphis domestica*: F7B751; *Gorilla gorilla gorilla*: G3R542; *Capra hircus*: A0A452E207; *Macaca fascicularis*: A0A2K5TZ15; *Ailuropoda melanoleuca*: G1LVN9; *Bos taurus*: F1N5B2; *Vulpes vulpes*: A0A3Q7S8U5; *Ornithorhynchus anatinus*: F6W2A3; *Cavia porcellus*: H0VCJ2; *Homo sapiens*: P25092.

Prediction of Three-Dimensional Structures of Human and Horse GC-C {#S2.SS7}
------------------------------------------------------------------

P25092 and A0A3Q2L9C5 UniProt entry sequences were used to model three dimensional structures of human and horse GC-C, respectively. Fold-recognition modeling was performed using I-Tasser ([@B59]), the best structural templates being 4PE5A, 5IJOJ, 5YFPB, 5VCHA, 5UOWB, 4UQQA, 5DLQB, 5YFPD, 4R04A, 6R3QA, and 6R3QA, 5OYHA, 4R04A, 5O5LA, 5IJOJ, respectively for human and horse. Structure refinement of the predicted models was carried out using ModRefiner ([@B58]). Energy minimization of output models was performed with GROMOS 96 forcefield ([@B52]), and models of GC-C were eventually submitted to PROCHECK ([@B31]) for backbone structure validation. Transmembrane domains were predicted using TMHMM Server v. 2.0 ([@B30]).

Docking Analysis of Linaclotide to GC-C {#S2.SS8}
---------------------------------------

The predictive models of the complexes between human or horse GC-C and linaclotide (retrieved from PubChem: ([@B27]) was computed by docking the drug to the fold-recognition models of the protein. Rigid docking was performed using PatchDock server ([@B45]), human or horse GC-C and linaclotide being uploaded as receptor and ligand, respectively. FireDock was used for interaction refinement. Settings were always kept to default values ([@B5]; [@B38]). The best scoring complex and all images were rendered with PyMOL (The PyMOL Molecular Graphics System, Version 1.3 Schrödinger, LLC).

Results {#S3}
=======

[Figure 1](#F1){ref-type="fig"} shows the relative expression distribution of guanylin (*GUCA2A*), uroguanylin (*GUCA2B*) and guanylate cyclase-C (*GUCY2C*) transcripts in 14 regions of the horse gastrointestinal tracts. The expression values are normalized with two reference genes (*SDHA* and *HPRT*). Reference genes showed relatively high stability with M value of 0.23, far below the accepted threshold as stated by [@B54]. A common pattern of expression was observed throughout the gastrointestinal tract for all three investigated transcripts. The expression was higher in jejunum, ileum, descending colon and rectum, and lower in the stomach.

![Gene expression throughout the gastrointestinal tract: the *x*-axis shows the different intestinal segments; the relative expression in log2 normalized for the two reference genes is indicated below the graph. The stomach, tissue with the lowest expression of all three genes, was set as calibrator. In the *y*-axis is indicated the relative expression in log2 scale.](fphys-10-01237-g001){#F1}

qRT-PCR results from bulk sample analyses ([Figure 1](#F1){ref-type="fig"}) allowed us to reduce from 14 to 6 gastrointestinal tracts the gene expression analysis. These six tissues were further investigated using individual samples ([Figure 2](#F2){ref-type="fig"}) to evaluate the individual variability that is lost with bulk solutions.

![Bar charts representing the relative expression value of *GUCA2A* **(A)** *GUCA2B* **(B)** and *GUCYC2* **(C)**: the *x*-axis shows six different intestinal tracts; the relative expression for the six horses for each of the 3 genes tested, normalized for the two reference genes, is also indicated below the graph. The left ventral colon, tissue with the lowest expression, was set as calibrator. In the *y*-axis is indicated the relative expression value with standard deviation. Bars marked with an asterisk indicate significant statistical difference (^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.001).](fphys-10-01237-g002){#F2}

As shown in [Figures 2A--C](#F2){ref-type="fig"}, the expression levels in tissues from six horses were comparable in bulk and individual samples. The individual variability is indicated by the values of standard error. The same expression pattern was observed with the highly expressed tissue ranging from 10 to 20 times compared to the calibrator for *GUCA2A*, from 3 to 15 for *GUCA2B* and of about 3 for *GUCYC2*. Difference in relative expression between genes can be seen in [Figure 1](#F1){ref-type="fig"}, the pelvic flexure behaving like the other tissues in terms of pattern and having mild relative expression values.

Changes in the relative expression for the three genes were checked for statistical significance with ANOVA. [Figure 2](#F2){ref-type="fig"} shows that statistically significant differences are reached only for *GUCA2B* in the highlighted comparisons.

Being GC-C receptor a promising therapeutic target, its protein expression levels were measured through western blotting. Results reported in [Figure 3](#F3){ref-type="fig"} confirm the expression pattern above described for the GC-C receptor.

![Protein expression of GC-C receptor in horse intestine. Detection of the levels of *GUCY2C* in stomach (1), duodenum (2), jejunum (3), ileum (4), body of cecum (5), left and right dorsal colon (6 and 7, respectively), left ventral colon (8), pelvic flexure (9), transverse colon (10), descending colon (11) and rectum (12). The densitometric analysis derives from six separate blots and a representative immunoblot is shown. Equal protein loading was verified by using an anti β-actin antibody. The detection was executed by an ECL western blotting analysis system. Data points marked with an asterisk indicate statistically significant differences with respect to the stomach, tissue with the lowest levels of GC receptor (^∗^*p* \< 0.05).](fphys-10-01237-g003){#F3}

Protein Alignment {#S3.SS1}
-----------------

Sequence alignment using Clustal Omega showed that GC-C is highly conserved among species (see percent identity matrix, [Figure 4](#F4){ref-type="fig"}). Most interestingly, 86 and 88% identity, along with 98 and 94% high consensus homology, were observed in the guanylate cyclase and protein kinase catalytic domains ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}).

![Percent identity matrix of GC-C amino acid sequences from different mammals using Clustal Omega.](fphys-10-01237-g004){#F4}

Docking Analysis of Linaclotide to Guanylate Cyclase {#S3.SS2}
----------------------------------------------------

The high homology between human and horse GC-C (particularly in the case of the catalytic domains) was associated to highly conserved three-dimensional structures ([Figures 5A,B](#F5){ref-type="fig"}). Most interestingly, docking studies between the fold-recognition models of GC-C and linaclotide revealed a fully conserved binding mode between the ligand and the receptors, as evident from the superimposition of the complexes ([Figure 5C](#F5){ref-type="fig"}). Specifically, the guanylate cyclase catalytic domain was calculated to be the most likely to accommodate the linaclotide molecule. This common behavior suggested a similar effect of the drug both in humans and horses.

![Comparison of complexes formed between either horse **(A)** or human GC-C **(B)** and linaclotide obtained by molecular docking. Cyclase and kinase catalytic domains are highlighted as blue and red ribbon, and corresponding binding regions are traced by linaclotide and GTP, respectively. Predicted transmembrane domains are highlighted in orange. Superimposition of the catalytic domains of human and horse guanylate cyclase complexed with linaclotide **(C)**.](fphys-10-01237-g005){#F5}

Discussion {#S4}
==========

The activation of the GC-C/cGMP pathway *via* guanylin and uroguanylin has been well established in various species; this pathway was shown to be essential in the restoration of mucosal barrier function during intestinal disorders, and the administration of synthetic agonists of this cascade can have beneficial effects. Being an essential prerequisite for their use, organ expression of *GUCA2A*, *GUCA2B* and *GUCYC2* has been investigated in previous studies in laboratory animals and humans ([@B57]; [@B23]; [@B21]).

In the present study we found high expression of both mRNAs of *GUCA2A* and *GUCA2B*, with uroguanylin generally displaying higher levels with respect to guanylin. The highest expression was found in jejunum and ileum, whereas lower levels were observed in the small colon (descending colon), left ventral colon (ascending colon), and rectum. From these results, we can reasonably state that horse stomach has the lowest expression of guanylin mRNA as already established in other species such as opossum and humans.

Similarly to other animals, the highest expression level was detected in the ileum, whereas horses showed a high expression in the colon comparable to humans, rats and mice but different from the opossum ([@B57]; [@B23]; [@B21]). Concerning uroguanylin, horses had higher expression in the large compared to the small intestine (upper tract), differently from other laboratory animals but similarly to the opossum ([@B28]; [@B23]; [@B21]).

Our data suggest that outcomes from clinical studies for the activity of guanylin in the different gastrointestinal tracts of laboratory animals can be translated to the equine species; however, caution should be used regarding uroguanylin.

The expression pattern for *GUCY2C*, the gene encoding for the GC-C receptor, was highest in the jejunum, ileum, left ventral colon, descending colon and rectum nevertheless the large individual variability did not allow to achieve statistical significance. These findings are of considerable clinical interest, since the distal tract of the small intestine and the large intestine are more frequently affected by constipation in this species ([@B7]). Orally administered linaclotide, a selective agonist of GC-C, elicited a significant, dose-dependent increase in gastrointestinal transit rates in rats ([@B13]). This drug is currently administered orally in humans for the treatment of irritable bowel syndrome (IBS) with constipation and for chronic constipation, due to its ability to stimulate fluid secretion and accelerating transit ([@B4]; [@B35]; [@B6]; [@B24]). Interestingly, linaclotide can also induce peripheral visceral analgesia by activation of a GC-C/extracellular cGMP pathway ([@B24]). Recently, a novel synthetic analog of human uroguanylin, plecanatide, received its first approval in the United States for the treatment of adult patients with chronic idiopathic constipation and IBS with constipation ([@B3]; [@B39]). Future clinical trials in horses are warranted to understand biochemical implication of the variance in expression of the GC-C ligands across the gut.

Colonic impaction is a frequent cause of colic in horses, and its medical treatment may include several options such as oral and intravenous administration of fluids, laxatives, mineral oil and drugs for the control of visceral pain ([@B25]). The use of common prokinetic drugs to treat horses with colonic impactions is controversial, because of the risk for intestinal rupture and pain worsening ([@B25]). A recent study investigated an alternative approach to horse colonic impaction and reported the preliminary positive effects on motility of prucalopride, a drug acting as high-affinity agonist of serotonin receptors (5-HT4) ([@B34]). However, the activation of GC-C receptors on horse epithelial intestinal surface could lead to four simultaneous actions (e.g., softening of the feces, transit acceleration, pain relieving and mucosal barrier restoration) resulting in a more proficient and safer therapeutic approach to this condition.

Motility enhancing and transit improving drugs have been advocated to treat postoperative ileus (POI) in horse ([@B43]). The prevalence of POI is as high as 53% and it is the reason for euthanasia or death for up to 43% of horses that undergone abdominal surgery ([@B42]). Since recent preclinical studies suggest the use of linaclotide for treatment of POI in human ([@B51]), the present demonstration of GC-C receptors in horses, together with the high identity/homology of GC-C catalytic domains among species ([Figure 4](#F4){ref-type="fig"}) could open new scenarios to treat this severe condition in horses and other species ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}).

Pharmacological activation of GC-C could also be of benefit in duodenitis-proximal jejunitis, grass sickness and other hypomotility condition where prokinetics are indicated ([@B26]; [@B43]; [@B34]).

Drugs able to accelerate transit could also shorten the length of hospitalization of sick horses, thereby reducing the cost of treatment and the number of potential complications, such as weight loss, thrombophlebitis, and laminitis in case of the abovementioned diseases ([@B43]). Unfortunately, specific information pertinent to equines is limited and must be extrapolated prudently from other species, included humans, because of the important differences in anatomy and physiology ([@B43]).

Thus, the demonstration of gene expression pattern of guanylin, uroguanylin and GC-C receptors in the horse intestine could open new ways for the therapeutic approach to horse gastrointestinal diseases by GC-C agonist, offering the advantage of accelerating transit together with pain control. Acting directly on the epithelial surface, GC-C agonists are little or not at all adsorbed in the blood, limiting the possibility of side effect in other organs ([@B51]). This is not the case of all other drugs currently available. Furthermore, GC-C synthetic agonists have the advantage to be administered on a daily basis. This is particularly useful in inappetent animals in which the drug could be administrated by nasogastric intubation. Donkeys are normally treated like small horses but they have many peculiarities in incidence, presentation and treatment of diseases ([@B33]). Nevertheless, since they have similar gastrointestinal physiology (herbivorous but monogastric) and can be affected by diseases causing life-threatening hypomotility (e.g., hyperlipidemia), the development of these kind of drugs could give advantages also in the management of these animals.

Interestingly, the receptor GC-C has been also demonstrated as a tumor suppressor, and has emerged as a promising target for intestinal and pancreatic cancer ([@B29]; [@B2]). The identification of GC-C receptors in horses as well as, in future, in other domestic species commonly affected by this type of cancer, could be an interesting field of study for new conservative therapies to be used in veterinary medicine.

Conclusion {#S5}
==========

This study demonstrated for the first time the expression of genes encoding for guanylin, uroguanylin and GC-C receptor in the intestinal tract of horses. The highest expression levels were found in the distal tract of the small intestine and in the large intestine. These findings might open new scenarios for translational therapeutic approach to some enteric diseases in this species. In fact, available bioinformatics tools can be of great help in assessing the inter-species structural homology of pharmacological targets of interest. Case-in-point, the computational analysis of conserved amino acid residues of GC-C receptor and its binding to linaclotide provided a solid rationale (in terms of drug-receptor interaction) supporting its therapeutic use. Studies further exploring these possibilities are currently in progress.
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